{
    "2018-10-22": [
        [
            {
                "time": "2018-11-02",
                "original_text": "Novartis Announces Full Data From LIBERTY Study Of Aimovig",
                "features": {
                    "keywords": [
                        "LIBERTY",
                        "Aimovig",
                        "data",
                        "study"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-18",
                "original_text": "Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates",
                "features": {
                    "keywords": [
                        "Q3",
                        "earnings",
                        "revenues",
                        "beat",
                        "estimates"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-18",
                "original_text": "How Novartis’s Innovative Medicines Business Performed in Q3",
                "features": {
                    "keywords": [
                        "Innovative Medicines",
                        "Q3",
                        "performed"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-18",
                "original_text": "How Novartis’s Business Segments Performed in the Third Quarter",
                "features": {
                    "keywords": [
                        "Business Segments",
                        "Third Quarter",
                        "performed"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-18",
                "original_text": "Novartis Reports Third-Quarter Revenue Growth",
                "features": {
                    "keywords": [
                        "Third-Quarter",
                        "Revenue Growth"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?",
                "features": {
                    "keywords": [
                        "BIIB",
                        "ALKS",
                        "Q3",
                        "Earnings",
                        "Due"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?",
                "features": {
                    "keywords": [
                        "BIIB",
                        "ALKS",
                        "Q3",
                        "Earnings",
                        "Due"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-10",
                "original_text": "This tiny biotech spun a quick $2 billion from $12 million",
                "features": {
                    "keywords": [
                        "tiny biotech",
                        "$2 billion",
                        "$12 million"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-05",
                "original_text": "Novartis Reveals New Data Analysis Of COMBI-AD Study Of Tafinlar With Mekinist",
                "features": {
                    "keywords": [
                        "COMBI-AD",
                        "Tafinlar",
                        "Mekinist",
                        "data analysis"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}